Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06362369 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
A Phase 1 study of Colorectal Cancer and Melanoma, sponsored by 7 Hills Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 4
- Study locations
NCT06362369 is a Phase 1 study of Colorectal Cancer and Melanoma that is actively recruiting participants, run by 7 Hills Pharma. The registered enrollment target is 126 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06362369, a Phase 1 study of Colorectal Cancer and Melanoma, is actively recruiting participants, sponsored by 7 Hills Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Alintegimod
Study Locations (4)
Florida
- Florida Cancer Specialists - Lake Mary
New Hampshire
- Dartmouth Hitchcock - Lebanon
Rhode Island
- Brown University Health Cancer Institute - Providence
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2024-08-23 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06362369
The ClinicalTrials.gov registry entry for NCT06362369 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (92% lower). The listed sponsor is 7 Hills Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT06362369 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, New Hampshire, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06362369 about?
NCT06362369 is a clinical study titled "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy". This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea...
What is the current status of trial NCT06362369?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2024-08-23. Estimated completion is 2028-12-31.
What conditions does trial NCT06362369 study?
This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma, Advanced Cancer.
What interventions are being tested in trial NCT06362369?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Alintegimod (DRUG).
Who is sponsoring clinical trial NCT06362369?
This trial is sponsored by 7 Hills Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06362369 being conducted?
This trial has 4 study locations across Florida, New Hampshire, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.